Pure Global

Xen 45 implant versus Deep Sclerectomy in the surgical treatment of open angle glaucoma: A comparative study in a South African tertiary hospital - Trial PACTR201906908757116

Access comprehensive clinical trial information for PACTR201906908757116 through Pure Global AI's free database. This Not Applicable trial is sponsored by University of the Witwatersrand Faculty of Health Sciences and is currently Recruiting. The study focuses on Eye Diseases.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Pan Africa Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
PACTR201906908757116
Not Applicable
Recruiting
procedure
Trial Details
Pan Africa Clinical Trials RegistryPACTR201906908757116
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Xen 45 implant versus Deep Sclerectomy in the surgical treatment of open angle glaucoma: A comparative study in a South African tertiary hospital

Study Focus

Eye Diseases

procedure

Sponsor & Location

University of the Witwatersrand Faculty of Health Sciences

Carnegie Corporation of New York

South Africa

Timeline & Enrollment

Not Applicable

Jan 01, 1900

Jan 01, 1900

Summary

Problem statementDeep sclerectomy augmented with MMC has a proven track record for use in open-angle glaucoma patients that require surgery to control their intraocular pressure, but the procedure is not without complications and is not always successful. Newer glaucoma surgical devices, of which the Xen 45 implant is an example, offer the following potential advantages over conventional surgery:• Shorter surgical time• Fewer complicationsThese benefits may improve the cost-effectiveness of the Xen 45 implant, an otherwise expensive device, but only if the device is equally effective in lowering IOP and if the requirements for post-operative follow-up visits, procedures and medications are comparable. It is not known, therefore, whether this procedure is a feasible alternative to deep sclerectomy in the resource-constrained setting of the Charlotte Maxeke Johannesburg Academic (CMJA) Hospital in Johannesburg, South Africa.Research QuestionIs the Xen 45 gel implant a cost-effective alternative procedure to deep sclerectomy at CMJA Hospital?Aim of the studyTo compare the cost-effectiveness of Xen implants versus deep sclerectomy in patients with open-angle glaucoma over a six-month period.Study objectivesPrimary objective• To cost Xen implant surgery and follow-up over a six-month period and compare it to the cost of deep sclerectomy surgery and six-month follow-up at CMJAH Secondary objectives• To compare IOP outcomes in the first two years after Xen implant surgery with those following deep sclerectomy surgery• To compare the success and failure rates of the two procedures at six months, one and two years post-operatively• To compare the post-operative requirement for glaucoma medication following Xen implants with that following deep sclerectomy surgery• To compare the complication (intra- and post-operative) rates of Xen implant surgery with deep sclerectomy surgery

ICD-10 Classifications

Disorders of eyelid in diseases classified elsewhere
Other disorders of eyelid
Other specified disorders of eyelid
Involvement of eyelid in other diseases classified elsewhere
Disorder of eyelid, unspecified

Data Source

Pan Africa Clinical Trials Registry

PACTR201906908757116

Non-Device Trial